ArticleFrontiers in aging neuroscience2026
Brain metabolic and network profiles characterized by comorbid depressive symptoms and sleep disturbances in Parkinson's disease: an
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a globally increasing neurodegenerative disorder. Its complex, multisystem pathophysiology extends beyond dopaminergic neuron loss and gives rise to diverse clinical manifestations. This exploratory study examined brain metabolic patterns in patients with PD and depressive symptoms (PD-Dep) or sleep disturbances (PD-SD). Methods: Twenty-eight patients with PD assessed between December 2019 and January 2024 were included. Sixteen met the HAMD threshold for PD-Dep, 21 met the PSQI threshold for PD-SD, and nine met both criteria; the cohorts were therefore overlapping symptom-defined groups. Seventeen healthy participants served as controls (HC). All participants underwent 18F-FDG PET. Voxel-wise group contrasts and exploratory AAL-based partial correlations with HAMD, PSQI, and UPDRS-III were examined. Results: At the prespecified liberal voxel-wise cluster-forming threshold, both symptom-defined PD groups showed extensive frontoparietal SUVR reductions relative to HC; these spatial findings should be considered exploratory. In PD-Dep, nominal HAMD associations included cortical and subcortical regions, whereas UPDRS-III associations were concentrated in frontoparietal regions. In PD-SD, nominal PSQI associations showed negative frontal/somatomotor and positive temporo-limbic patterns. The Yeo-network summaries were derived from symptom-correlated AAL regions, not from the voxel-wise group-contrast clusters. None of the regional correlations survived correction for multiple comparisons. Conclusion: The findings identify exploratory metabolic and network-level patterns associated with depressive symptoms and sleep disturbances in PD. The symptom-correlated regional distributions are compatible with, but do not validate, aspects of the body-first/brain-first framework. Larger independent cohorts, conventional voxel-wise thresholding, multiplicity-controlled analyses, and explicit adjustment for motor severity are required before symptom-specific mechanisms or PD subtypes can be inferred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.